[USA] Cardax, Inc. (“Cardax”) (OTCQB:CDXI) announced today that its astaxanthin consumer health candidates CDX-085 and ASTX-1F demonstrated more than two and one-half times higher oral bioavailability than a leading microalgal astaxanthin product in a head-to-head monkey study. The study was conducted by top-tier contract research organizations and bioavailability was determined by measuring the plasma exposure of astaxanthin over four days following a single dose.
“We are pleased to see the superior oral bioavailability of our product candidates in a scientifically rigorous study”
CDX-085 is a patented pure ester of nature-identical astaxanthin and ASTX-1F is a proprietary formulation of nature-identical astaxanthin. The enhanced bioavailability of CDX-085 and ASTX-1F compared to microalgal astaxanthin should reduce the size/number of capsules or tablets required to achieve equivalent circulating levels of astaxanthin.
Based on these results, the Company now intends to launch ASTX-1F as a first generation dietary supplement earlier in 2016 than previously expected, followed by CDX-085 as a second-generation dietary supplement and then OTC drug.
“We are pleased to see the superior oral bioavailability of our product candidates in a scientifically rigorous study,” said Cardax CEO, David G. Watumull. “CDX-085 and ASTX-1F provide an unmatched combination of bioavailability, purity, intellectual property, and large scale manufacturing advantages.”